On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

While billions pour into pharmaceutical biotech, officials and experts warn there’s much less private investment in products more relevant to the military, like body armor materials, anti-corrosion ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer Doudna – said it is focusing on NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential.In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 ...

A UCO team has applied the genome editing technique, which garnered a Nobel Prize in Chemistry in 2020, to unravel the ...